Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal combinatorial biologic therapies in immune-mediated inflammatory diseases (IMIDs)
2024-518011-19-01Phase 2Authorised
- Sponsor
- Cardiff University
- Start
- Oct 2025
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 2, single-arm trial of leuprolide in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), sponsored by Cardiff University. Primary endpoint: Disease remission at week 24. Planned start Oct 2025; status: authorised.
02
Drugs
leuprolide
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-518011-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518011-19-01.